Clinical Trials Logo

Clinical Trial Summary

The Purpose of this study is to determine the response to two different strengths of a topical gel containing nitroglycerin in patients with Raynaud's disease.


Clinical Trial Description

The Purpose of this clinical study is to determine, in a controlled fashion, the response to two dosage strengths of a topical gel formulation of Nitroglycerin, MQX-503, in the determination of changes in finger blood flow and skin temperature in the fingers of patients with moderate to severe primary Raynaud's phenomenon and with Raynaud's phenomenon secondary to autoimmune diseases, such as scleroderma. The dosage strength response in the treatment of the symptoms (pain, tingling, numbness) will also be monitored. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00378521
Study type Interventional
Source MediQuest Therapeutics
Contact
Status Completed
Phase Phase 2
Start date July 2006
Completion date July 2006

See also
  Status Clinical Trial Phase
Completed NCT00000530 - Raynaud's Treatment Study (RTS) Phase 3
Completed NCT00048763 - Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon Phase 4
Completed NCT00048776 - Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon Phase 4
Enrolling by invitation NCT02615964 - Nova Cold Hands Raynaud's Disorder, a Disease Which Results in Decreased Blood Flow to the Hands and Feet. N/A
Completed NCT01309802 - A Two-Part Study of BOTOX® Therapy for Ischemic Digits Phase 2
Completed NCT00480753 - Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon Phase 2
Completed NCT02396238 - Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR) N/A
Completed NCT00351117 - St. John's Wort in the Treatment of Raynaud's Phenomenon Phase 3
Completed NCT00528242 - Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease Phase 2
Completed NCT02683408 - Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon N/A
Active, not recruiting NCT00577304 - A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon Phase 3
Completed NCT00419419 - Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon Phase 3
Completed NCT00266669 - Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon Phase 3
Completed NCT01090492 - PF-00489791 For The Treatment Of Raynaud's Phase 2